NDA 022250 · Merz
Ampyra
Dalfampridine · Oral · Potassium Channel Blocker
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Nov 18, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Jan 22, 2010
Approved uses
1
Original approval plus efficacy supplements
Registered trials
85
32 Phase 3, 10 recruiting
FAERS reports
71,576
20,310 serious, 1,771 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 16, 2026.
AMPYRA is indicated as a treatment to improve walking in adult patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed [see Clinical Studies (14) ]. AMPYRA ® (dalfampridine) is a potassium channel blocker indicated to improve walking in adult patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed ( 1 , 14 ).
Mechanism: The mechanism by which dalfampridine exerts its therapeutic effect has not been fully elucidated. Dalfampridine is a broad spectrum potassium channel blocker. In animal studies, dalfampridine has been shown to increase conduction of action potentials in demyelinated axons through inhibition of potassium channels.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 22, 2010 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanReviewLabelOther Important Information from FDA
1 products under this application
- AMPYRA · DALFAMPRIDINE 10MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Dalfampridine" as an intervention, any sponsor and status, largest first.
BiogenBiogen (BIIB)
NCT01480076 · 901 participants · Start Feb 2012 · Primary completion Jul 2013
Drug: Fampridine · For: Multiple Sclerosis
Sites: Concord, Australia; Kogarah, Australia; Liverpool, Australia · 59 sites in all
- Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple SclerosisPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT02219932 · 646 participants · Start Sep 2014 · Primary completion Feb 2016
Drug: fampridine; Placebo · For: Multiple Sclerosis
Sites: Cullman, Alabama; Phoenix, Arizona; San Diego, California · 87 sites in all
- Study of Fampridine-ER Tablets in Patients With Multiple SclerosisPivotal-lookingCompleted
Acorda TherapeuticsIndustry
NCT01328379 · 430 participants · Start Mar 2011 · Primary completion Apr 2012
Drug: Dalfampridine-ER 5mg; Dalfampridine-ER 10mg · For: Multiple Sclerosis
Sites: Cullman, Alabama; Phoenix, Arizona; Sun City, Arizona · 70 sites in all
- A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.Pivotal-lookingCompleted
Acorda TherapeuticsIndustry
NCT02271217 · 377 participants · Start Dec 2014 · Primary completion Sep 2016
Drug: Placebo; dalfampridine-ER 7.5mg and 1 more · For: Post-Ischemic Stroke
Sites: Gilbert, Arizona; Berkeley, California; Long Beach, California · 74 sites in all
- Study of Oral Fampridine-SR in Multiple SclerosisPivotal-lookingCompleted
Acorda TherapeuticsIndustry
NCT00127530 · 300 participants · Start May 2005 · Primary completion Jun 2006
Drug: Fampridine-SR; Placebo · For: Multiple Sclerosis
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 34 sites in all
- Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.Pivotal-lookingTerminated
Acorda TherapeuticsIndustry
NCT02422940 · 294 participants · Start Apr 2015 · Primary completion Jan 2017
Drug: dalfampridine-ER 7.5 mg; dalfampridine-ER 10 mg · For: Post-ischemic Stroke
Sites: Gilbert, Arizona; Berkeley, California; Carlsbad, California · 66 sites in all
- Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 TrialPivotal-lookingCompleted
Acorda TherapeuticsIndustry
NCT00648908 · 269 participants · Start Jun 2006 · Primary completion Jan 2011
Drug: Fampridine-SR · For: Multiple Sclerosis
Sites: Phoenix, Arizona; Los Angeles, California; Sacramento, California · 32 sites in all
- Study of Fampridine-SR Tablets in Multiple Sclerosis PatientsPivotal-lookingCompleted
Acorda TherapeuticsIndustry
NCT00483652 · 240 participants · Start May 2007 · Primary completion Feb 2008
Drug: Fampridine-SR; Placebo · For: Multiple Sclerosis
Sites: Phoenix, Arizona; Fayetteville, Arkansas; Berkeley, California · 40 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- gait disturbance10,994
- drug ineffective8,325
- fall7,361
- fatigue5,556
- balance disorder4,909
- multiple sclerosis relapse4,788
- therapy cessation4,511
- dizziness4,000
- urinary tract infection3,747
- condition aggravated3,514
- asthenia3,471
- insomnia3,311
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 6 |
| 2010 | 686 |
| 2011 | 837 |
| 2012 | 1,050 |
| 2013 | 1,618 |
| 2014 | 6,349 |
| 2015 | 7,532 |
| 2016 | 12,012 |
| 2017 | 10,164 |
| 2018 | 10,789 |
| 2019 | 7,166 |
| 2020 | 3,152 |
| 2021 | 2,695 |
| 2022 | 2,758 |
| 2023 | 2,247 |
| 2024 | 992 |
| 2025 | 748 |
| 2026 | 772 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ampyra (Dalfampridine)
2024 spending
$40.3M
Beneficiaries
1,046
6,957 claims
Per beneficiary
$38,490
$69.40 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $72,053,833 |
| 2021 | $55,939,976 |
| 2022 | $48,646,409 |
| 2023 | $44,351,232 |
| 2024 | $40,260,360 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis.
Rindi LV, Zaçe D, Braccialarghe N, et al. · Drug Saf 2024 · Systematic Review, Meta-Analysis
- Episodic Ataxias: Primary and Secondary Etiologies, Treatment, and Classification Approaches.
Hassan A · Tremor Other Hyperkinet Mov (N Y) 2023 · Systematic Review, Case Reports
- Dalfampridine benefits ambulation but not cognition in multiple sclerosis.
Satchidanand N, Drake A, Smerbeck A, et al. · Mult Scler 2020 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Predicting responsiveness to fampridine in gait-impaired patients with multiple sclerosis.
Filli L, Werner J, Beyer G, et al. · Eur J Neurol 2019 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Effect of dalfampridine on information processing speed impairment in multiple sclerosis.
De Giglio L, De Luca F, Gurreri F, et al. · Neurology 2019 · Multicenter Study, Randomized Controlled Trial
- Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
Limone BL, Sidovar MF, Coleman CI · Health Qual Life Outcomes 2013 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Merz
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.